Teriparatide in athlete stress fracture healing: a case report and review of literature

Teriparatide, a recombinant human parathyroid hormone (rhPTH), is primarily used to treat osteoporosis but is also being investigated for its potential to accelerate fracture healing in athletes. This review examines the current evidence supporting Teriparatide’s efficacy in treating stress fractures in athletes. The first reported use of Teriparatide in this context was documented in a 2015 case series, where five athletes with metatarsal stress fractures experienced significant pain reduction and increased bone mineral density after six weeks of treatment. Subsequent studies, including a series involving metatarsal fractures and a randomized controlled trial with tibial fractures, have shown similar benefits, including decreased fracture size and enhanced bone density. However, despite these promising results, there is a need for more extensive research, particularly large, randomized controlled trials, to confirm these findings. A case report of a 43-year-old marathon runner demonstrated complete fracture healing and return to activity after four months of Teriparatide treatment. In conclusion, Teriparatide shows potential as a treatment to accelerate fracture healing in athletes, but further research is necessary to establish its efficacy and safety fully. Athletes considering this treatment should consult with their healthcare providers to understand the risks and benefits